Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas
about
Mast cells in meningiomas and brain inflammationLoss of the protein-tyrosine phosphatase DEP-1/PTPRJ drives meningioma cell motilitycDNA cloning and chromosomal mapping of a predicted coiled-coil proline-rich protein immunogenic in meningioma patientsMeningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressorComplex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets.Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.Novel immunogenic antigens increase classification accuracy in meningioma to 93.84%.Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma.MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies.Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas.Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas.Endometriosis: a new cellular and molecular genetic approach for understanding the pathogenesis and evolutivityNPHP4, a cilia-associated protein, negatively regulates the Hippo pathwayMeningioma pathology, genetics, and biology.Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.Diagnostic and molecular pathology of meningiomas.Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningiomaAnalysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression.Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors.Genomic landscape of high-grade meningiomas.Classification of human meningiomas: lights, shadows, and future perspectives.Checkpoint inhibition in meningiomas.Genetic landscape of meningioma.The Emerging Role of TRAF7 in Tumor Development.SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors.Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression.Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors.Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival.Genetics of familial and non-familial skull base tumours.Calpain-dependent proteolysis of merlin occurs by oxidative stress in meningiomas: a novel hypothesis of tumorigenesis.Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas.Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer.The human chromosome 22-located genes and malignancies of the central nervous system.Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.Characterization of the mouse beta-prime adaptin gene; cDNA sequence, genomic structure, and chromosomal localization.
P2860
Q21146660-D397D2B7-A7C1-4199-848C-6BC836863967Q24307712-C5A62C1E-1DFB-4C3E-8FDB-34B1ECB7B829Q24323883-18F79C9A-4A6D-435A-BFD6-A072A2A8B556Q26741529-85D44328-30F7-47E9-8F70-E18E10A46C66Q27675130-15DF7E05-6AAF-480B-A428-BBD681B63190Q30855737-0D8FDFC9-7CEB-4E6E-884F-FEE254625A78Q33480310-3553F8FC-25D3-4C5C-91DF-2A78C94366CCQ33588789-B8FAAFA8-D4EC-4A33-B366-E3E4FBBF7ADEQ34085362-75EBB3AB-4D3B-4D15-9A18-D8AF1FA3A84CQ34110478-8F56DBCC-D284-41C7-97A3-452EB5E670B4Q34116094-E167D248-361C-4B3A-8891-D802F1C915D5Q34716061-D5A2E132-41DF-4F6F-99F2-16259624E612Q34867977-73C461F9-D0EA-44A0-BBCE-188F31F40AF4Q35196050-04B3E7BA-24C3-4B56-8257-E09B772927EEQ35751662-B60BC3BC-8D13-4770-8979-5FD31B91EDF8Q36327729-EBBE6372-1156-49CA-BEC2-452E02CC1B58Q36477494-89A02CF5-FF57-4E1D-A328-A37D0024427FQ36673027-B5EF0DDE-E130-4B28-B1EB-216BC0DA9169Q36761277-6FD2CA5D-E75D-401A-99DC-E51E50A5658BQ36785144-213A2F27-E6F9-41F5-81AD-19A602305811Q36830940-6E34CF86-CDA6-41BF-BF87-38268E59CDD8Q37999071-810D5C04-6F5C-4688-9C5B-D13814A9008DQ38676440-D92CBA06-1C73-4251-9567-F9E1107EC8C7Q38810583-5ACE4CC2-AC65-4765-AA73-D5D44D6C5C65Q38838646-8BA9FD71-C7A4-4572-A355-7070DEAA2099Q38953562-E13ADB76-9C90-4EEE-AC5C-EFD96F180982Q38997320-443325E7-1F9D-4A64-AFA6-EC9AC1F2EE62Q39023691-60A05D29-ED35-4BF8-AE86-A7D32CAFF673Q39298204-CF2B969F-6378-47C6-B7F9-0A7272C25503Q40462570-3F27606C-78BA-4214-9FC7-89507B24F2EFQ40479891-CDF49B5A-2B5A-4C2B-B9F0-6ADCE2ED23A5Q40494023-A3885412-4F35-47FE-9E00-4F743DDA46B2Q40549515-72AEE4BA-392D-447C-8B14-333A2B964970Q40763254-F97909EA-E982-41EC-A94F-71B21EFF5AE5Q40764834-5AB1FDF2-ADBD-4828-9075-3A7BBB1D5648Q40827716-E7403691-6EC4-49F1-97C9-27FEE39F66DAQ41225741-D1730ADA-7453-4361-AA92-5583FFA3AD04Q41705181-D31295DE-0773-42D7-B504-09047C4B9852Q42445998-4993C3E8-C021-419E-AEBC-F86FCEB9FAB1Q42662548-C090E967-6F1E-498F-B1C6-97F454239563
P2860
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas
description
article
@en
im Februar 1994 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 1994
@uk
name
Evidence for the complete inac ...... jority of sporadic meningiomas
@en
Evidence for the complete inac ...... jority of sporadic meningiomas
@nl
type
label
Evidence for the complete inac ...... jority of sporadic meningiomas
@en
Evidence for the complete inac ...... jority of sporadic meningiomas
@nl
prefLabel
Evidence for the complete inac ...... jority of sporadic meningiomas
@en
Evidence for the complete inac ...... jority of sporadic meningiomas
@nl
P2093
P2860
P356
P1433
P1476
Evidence for the complete inac ...... jority of sporadic meningiomas
@en
P2093
Collins VP
Rangaratnam S
Ruttledge MH
Sarrazin J
P2860
P2888
P304
P356
10.1038/NG0294-180
P407
P577
1994-02-01T00:00:00Z